explore -WSS

explore

author：knowledge 2025-09-28 23:45:00 - browse：1356

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Sage hopes for a blockbuster in antidepressant now before FDA

entertainment

WSS

Sage hopes for a blockbuster in antidepressant now before FDA

Vertex non

Germany receives 178 compensation applications from gay servicepeople over discrimination

Ohioans vote in high

Astronauts get first look at the spacecraft that will fly them around the moon

Amazon expands telehealth clinic nationwide

entertainment

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

‘Oppenheimer’ and the risks of AI in health care

Drug repurposing or repositioning? The language matters

The high personal cost of affirmative action for Black doctors

Drug repurposing or repositioning? The language matters

CDC launches VaccineFinder tool to locate Covid

Moonlake's readout produced a cash windfall. Risks remain

Travel bans should be based on evidence, not politics or fear

23andMe had bad news about my health. I wish a person had delivered it

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

entertainment

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Judge rejects Trump's counterclaim against E. Jean Carroll

CDC launches VaccineFinder tool to locate Covid

Sage hopes for a blockbuster in antidepressant now before FDA

FTX founder Sam Bankman

hotspot

focus

entertainment

hotspot